• Kewal K. Jain


It is important to realize that cancer is not just one but many different diseases, each with distinct characteristics and therapeutic requirements. Genomic research has provided a stratification of cancer types. Genomics as applied to cancer or oncogenomics provides an unprecedented opportunity for the discovery of potential new targets. Through the establishment of a suite of research programs, the National Cancer Institute (NCI) of the USA is developing the interface of genomics and cancer. The components of the program, including the Cancer Genome Anatomy Project (CGAP), the Cancer Molecular Analysis Project, and the Initiative in Chemical Genetics, provide a platform for the integration of basic and clinical research for the benefit of patients’ health. Oncogenomics has assumed importance as a guide to management and development of personalized cancer therapies. Gene expression profiling of tumors is also used for developing targeted anticancer therapies.


Renal Cell Carcinoma Tumor Suppressor Gene Checkpoint Pathway DHFR Gene Normal Human Mammary Epithelial Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Martianov I, Ramadass A, Serra Barros A, et al. Repression of the human dihydrofolate reductase gene by a non-coding interfering transcript. Nature 2007;445:666-70.CrossRefGoogle Scholar
  2. Peña-Llopis S, Christie A, Xie XJ, Brugarolas J. Cooperation and Antagonism among Cancer Genes: The Renal Cancer Paradigm. Cancer Res 2013;73;4173-9.CrossRefGoogle Scholar
  3. Perera D, Tilston V, Hopwood JA, et al. Bub1 Maintains Centromeric Cohesion by Activation of the Spindle Checkpoint. Developmental Cell 2007;13:566-79.CrossRefGoogle Scholar
  4. Rai R, Dai H, Multani AS, et al. BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell 2006;10:1-13.CrossRefGoogle Scholar
  5. Raychaudhuri P, Park HJ. FoxM1: A Master Regulator of Tumor Metastasis. Cancer Res 2011;71:4329-33.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Kewal K. Jain
    • 1
  1. 1.Jain PharmaBiotechBaselSwitzerland

Personalised recommendations